On Sunday, Russia announced they have finished conducting coronavirus vaccine clinical trials.
This means, the efficacy of the drug on humans is now known to Russia. Moscow archives this feat amid global attention towards the West for the first vaccine to mass immunize against the novel coronavirus.
Chief researcher at Russia’s Sechenov University told media outlet TASS that the vaccine’s efficacy on humans was known on Sunday after the clinal trials were completed on volunteers. As of now, the volunteers will be under medical supervision on an outpatient basis after being discharged.
“The research has been completed and it proved that the vaccine is safe. The volunteers will be discharged on July 15 and July 20,” Elena Smolyarchuk told TASS, who heads the Center for Clinical Research on Medications at Sechenov University.
The clinical trials of the vaccine, produced by Russia’s Gamalei Institute of Epidemiology and Microbiology was started on July 18, according to reports. Clinical trials determine the safety of the vaccine on humans. In this case, the vaccine has been deemed safe for human application.
“The safety of the vaccine is confirmed. It corresponds to the safety of those vaccines that are currently on the market,” Vadim Tarasov, the director of the Institute for Translational Medicine and Biotechnology, told Sputnik.
(This is a developing story. More to follow)